Related Experiment Video
Updated: May 10, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Efficacy of fixed low dose hydroxyurea in Indian children with sickle cell anemia: a single centre experience
Dipti L Jain1, Mohini Apte, Roshan Colah
1Department of Pediatrics, Government Medical College, Nagpur; and * National Institute of Immunohaematology, Mumbai, India. Correspondence to: Dr Dipti Jain,Professor, Department of Pediatrics, Governement Medical College, Nagpur, Maharashtra 440 003, India. drvijayasarathi@gmail.com.
Insights
Fixed low-dose hydroxyurea (HU) effectively improved fetal hemoglobin and reduced clinical events in Indian children with sickle cell anaemia (SCA). The treatment was found to be safe over a two-year follow-up period.
Area of Science:
- Pediatric Hematology
- Sickle Cell Disease Research
- Pharmacological Interventions
Background:
- Limited data exists on hydroxyurea (HU) efficacy in Indian children with sickle cell anaemia (SCA).
- Evaluation of fixed low-dose HU is crucial for this specific pediatric population.
Purpose of the Study:
- To assess the efficacy and safety of a fixed low dose of hydroxyurea (HU).
- To evaluate hematological and clinical outcomes in Indian children with severe sickle cell anaemia (SCA).
Main Methods:
- A cohort of 144 children (<18 years) with severe SCA received fixed low-dose HU (10 mg/kg/day).
- Participants were monitored for two years for hematological and clinical efficacy and safety parameters.
- Key metrics included fetal hemoglobin (HbF%), total hemoglobin, MCV, vasoocclusive crises, blood transfusions, and hospitalizations.
Main Results:
- Significant increases in HbF%, total hemoglobin, and mean corpuscular volume were observed.
- Marked reductions in vasoocclusive crises, blood transfusions, acute chest syndrome, sequestration crises, and hospitalizations occurred.
- No major adverse events were reported, indicating a favorable safety profile.
Conclusions:
- Fixed low-dose hydroxyurea (HU) demonstrates significant efficacy in improving hematological markers.
- HU treatment led to a substantial decrease in clinical complications and hospitalizations in Indian children with SCA.
- The study confirms that fixed low-dose HU is a safe and effective therapeutic option for pediatric SCA in India.
Introduction:
Data on the efficacy of hydroxyurea (HU) in Indian children with sickle cell anaemia (SCA) is limited. Hence, we have evaluated the efficacy of fixed low dose HU in Indian children.
Methods:
The study cohort consisted of 144 children (<18 years of age) with SCA having severe manifestations (≥ 3 episodes of vasocclusive crisis or blood transfusions, or having ≥ 1 episode of acute chest syndrome or cerebrovascular stroke or sequestration crisis) who were started on fixed low dose HU (10 mg/kg/day). They were followed up for two years and monitored for the hematological and clinical efficacy and safety.
Results:
There was significant increase in the fetal hemoglobin level (HbF%), total hemoglobin and mean corpuscular volume. Vasoocclusive crises, blood transfusions, acute chest syndrome, sequestration crises and hospitalizations decreased significantly. Baseline HbF% had significant positive correlation with HbF% at 24 months. There was significant negative correlation between baseline HbF% and change in HbF% from baseline to 24 months. No significant correlation was found between HbF% at baseline and clinical event rates per year after HU. No major adverse events occurred during the study period.
Conclusions:
Fixed low dose HU is effective and safe in Indian children with SCA.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Hemodialysis II: Procedure and Complications
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
